Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemzoparlimab in AML/MDS
NCT04912063Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jun 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of lemzoparlimab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (7 arms), sponsored by AbbVie Inc. Primary endpoint: Dose Limiting Toxicities up to 30 days. Started Jun 2021; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04912063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912063.